Background: Diabetic Kidney Disease (DKD) represents the major cause Chronic Kidney Disease (CKD) where 5-40% of patients with Type 2 Diabetes Mellitus (T2DM) ultimately develop DKD. CKD diagnosis is reliable on levels of blood urea nitrogen and serum creatinine, however, serum creatinine has a low predictive value in early detection of renal impairment. So, new biomarkers for early diagnosis of CKD is of interest. Our objective is to elucidate the significance of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as an early predictor of diabetic nephropathy in comparison with albuminuria in (T2DM). Methods: Prospective, case control study, carried out on patients with T2DM with a duration of disease ranged from (5-15) years, presented to outpatient clinics of nephrology and endocrinology units of internal medicine department in Zagazig University hospitals from August 2018 to February 2019. The study included (100) participants divided into: group (A) 25 healthy control, group (B) 75 diabetic type 2 patients stratified into three subgroups according to albumin / creatinine ratio: subgroup (1): 25 normoalbuminuric, subgroup (2): 25 microalbuminuric, subgroup (3): 25 macroalbuminuric. Results: There was statistically significant difference between healthy individuals, normo, micro and macroalbuminuria diabetic patients regarding serum NGAL (sNGAL) & urinary NGAL (uNGAL), where their levels incremented parallel to the degree of albuminuria. Conclusion: tubular injury may precede glomerular injury in diabetic patients and As NGAL is a tubular marker, So NGAL is superior to albumin / Creatinine ratio (ACR) as an early predictor of DKD among T2DM patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.